Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis ; volume:73 ; number:10 ; day:6 ; month:8 ; year:2024 ; pages:1-13 ; date:10.2024
Cancer immunology immunotherapy ; 73, Heft 10 (6.8.2024), 1-13, 10.2024
- Urheber
-
Guo, Guangzhong
Zhang, Ziyue
Zhang, Jiubing
Wang, Dayang
Xu, Sensen
Liu, Guanzheng
Gao, Yushuai
Mei, Jie
Yan, Zhaoyue
Zhao, Ruijiao
Wang, Meiyun
Li, Tianxiao
Bu, Xingyao
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00262-024-03774-7
- URN
-
urn:nbn:de:101:1-2411292101292.310326908832
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Guo, Guangzhong
- Zhang, Ziyue
- Zhang, Jiubing
- Wang, Dayang
- Xu, Sensen
- Liu, Guanzheng
- Gao, Yushuai
- Mei, Jie
- Yan, Zhaoyue
- Zhao, Ruijiao
- Wang, Meiyun
- Li, Tianxiao
- Bu, Xingyao
- SpringerLink (Online service)
Ähnliche Objekte (12)
Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab
Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma
Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response
Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition
Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition
Tumor-infiltrierende Lymphozyten beim Glioblastoma multiforme
Glioblastoma vaccine tumor therapy research progress
Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors
Correction to: Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response
Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study
Tumor cell response to bevacizumab single agent therapy in vitro
Tumor cell response to bevacizumab single agent therapy in vitro
Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab
Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma
Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response
Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition
Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition
Tumor-infiltrierende Lymphozyten beim Glioblastoma multiforme
Glioblastoma vaccine tumor therapy research progress
Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors
Correction to: Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response
Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study
Tumor cell response to bevacizumab single agent therapy in vitro
Tumor cell response to bevacizumab single agent therapy in vitro
Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab
Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma
Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response
Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition
Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition
Tumor-infiltrierende Lymphozyten beim Glioblastoma multiforme
Glioblastoma vaccine tumor therapy research progress
Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors
Correction to: Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response
Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study
Tumor cell response to bevacizumab single agent therapy in vitro